In this week’s edition, we’re taking a look at what country is poised to be a global leader in cannabis cultivation… spoiler alert: it’s China. Also, why was the U.K.’s medical cannabis program such an epic failure? And will a surge of new Canadian cannabis products help boost the bearish market? All that and more in this week’s CBD Business Weekly Newsletter.
Enjoy!
China will emerge as the cannabis cultivating super power producing flower for as little a 10 cents a gram, a leading producer believes. Speaking at the Cannabis Investor Forum in the City of London Oliver Zugel, Executive Chairman and co-founder of Colombian producer Foliumed, elaborated on how he sees the cultivation industry developing in China.
“Hemp outdoor cultivation in the U.K. is a short-lived business with just one crop a year, in Colombia we can get up to five harvests a year but the Chinese will be beating us on price within a few years. Cultivating under lights is not sustainable, the carbon footprint of such operations is horrible, something like three per cent of all California’s electricity is taken by the cannabis industry.”
Click here to read the full story
Subscribe to the CBD Business Weekly Newsletter
One year on from the introduction of medical cannabis in the U.K., the overwhelming consensus is that it has been a massive failure in need of a complete overhaul. As things stand there is little chance of this coming from within the U.K. medical establishment so the change will need to come from elsewhere.
Click here to read the full story
Subscribe to the CBD Business Weekly Newsletter
It’s one year since recreational cannabis was legalized in Canada and the anniversary has been marked by introduction of a new range of cannabis products including; edibles, drinks and vapes. It will be a while before any go on sale – early December is predicted as they have to be individually approved by Health Canada. The market could be worth almost $3 billion a year, reports Health Europa.
Click here to read the full story
Subscribe to the CBD Business Weekly Newsletter
Alexej Pikovsky, of London firm Augmentum Partners, says there is 47 times more flower in inventory, or in the ground, than there are sales. Speaking at the Cannabis Investors Forum in London he went on to say that, “We have seen some 150 licenses approved in Portugal and there is going to be massive drop in flower prices – so, for investors it’s not really the place to be.”
Click here to read the full story
Subscribe to the CBD Business Weekly Newsletter
The post Chinese Cultivation, U.K. Medical Cannabis, Canada 2.0, and more – The CBD Business Weekly appeared first on Cannadelics.
Take two of the most hot-button, tendentious issues of our time – cannabis use and gun rights – combine them, and now we really have a debate. As the law currently stands, medical cannabis patients are not afforded their 2nd amendment right to bear arms. Technically, all cannabis consumers are banned from buying guns, but only medical […]
The post Owning Guns is a Constitutional Right, Unless You’re a Cannabis User appeared first on Cannadelics.
Cannabis policy changes in Africa are welcome. But small producers are the losers by Clemence Rusenga
Cannabis is a drug crop with a long history in Africa. Alongside coca and opium poppy, it has been subjected to international control for nearly a century. The International Opium Convention of 1925 institutionalised the international control system and extended the scope of control to cannabis. In 1961 a new international convention was adopted to […]
A link to your site, with your site's name and description as anchor text.
University of Sydney to Offer Free Cannabis Testing by Johnny Green
The University of Sydney is launching a fairly robust study in an attempt to, as the university describes it, “investigate cannabis consumption, behaviours, and attitudes among users.” Part of the study involves offering free, anonymous cannabis testing for people that cultivate their own cannabis in the Australian Capital Territory (ACT). Cannabis was decriminalized in 2020 in the […]
A link to your site, with your site's name and description as anchor text.